Evidence map›Paper›PMID 34523056›Full record

ArticleNeurochemical research2022

Medicarpin Protects Cerebral Microvascular Endothelial Cells Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury via the PI3K/Akt/FoxO Pathway: A Study of Network Pharmacology Analysis and Experimental Validation.

Yu Wang, Ronggang Yang, Feng Yan, Yeqiang Jin, Xu Liu, Tiancai Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Medicarpin and Homopterocarpin Isolated fromMolecules (Basel, Switzerland) · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yu WangDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China.
Ronggang YangDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China.
Feng YanDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China.
Yeqiang JinDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China.
Xu LiuDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China.
Tiancai WangDepartment of Critical Care Medicine, Nanshi Hospital of Nanyang, No.15 West Zhongzhou Road, Nanyang, 473000, China. wangtiancai2022@163.com.
Nanyang Institute of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicarpin, a pterocarpan class of naturally occurring phytoestrogen possesses various biological functions. However, the effect of medicarpin on oxygen-glucose deprivation-reoxygenation (OGD/R)-induced injury in human cerebral microvascular endothelial cells (HCMECs) remains largely unknown. Target genes of medicarpin were predicted from PharmMapper. Target genes of ischemic stroke were predicted from public databases GeneCards and DisGeNET. Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the intersecting targets was analyzed via DAVID 6.8. Cell viability was evaluated using CCK-8 assay. Malondialdehyde content, superoxide dismutase activity, and glutathione level were detected using corresponding commercially available kits. Cell death was assessed by TUNEL assays. Expression of protein kinase B (Akt), phosphorylated-Akt, forkhead box protein O1, phosphorylated-FoxO1, FoxO3a, and phosphorylated-FoxO3a (p-FoxO3a) was detected by western blot analysis. The intersecting targets of medicarpin and ischemic stroke were significantly enriched in phosphatidylinositol 3-kinase (PI3K)/Akt and FoxO pathways. Medicarpina attenuated OGD/R-evoked viability inhibition, oxidative stress, and cell death in HCMECs. Additionally, medicarpin activated the PI3K/Akt and FoxO pathways in OGD/R-induced HCMECs. Inhibition of PI3K/Akt pathway abrogated the neuroprotective effect of medicarpin on OGD/R-induced injury and activation of FoxO pathway in HCMECs. In conclusion, medicarpin suppressed OGD/R-induced injury in HCMECs by activating PI3K/Akt/FoxO pathway.

Indexed as

PterocarpansReperfusion InjuryApoptosisEndothelial CellsGlucoseHumansNetwork PharmacologyOxygenPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPhytoalexinsProto-Oncogene Proteins c-aktGlucosemedicarpinOxygenPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPhytoalexinsProto-Oncogene Proteins c-aktPterocarpansIschemic strokeMedicarpinNetwork pharmacologyOxygen-glucose deprivation-reoxygenationPI3K/Akt/FoxO pathway

Identifiers

PMID34523056
OpenAlexW3201078406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.